Author:
de Jesus Victor Hugo Fonseca,da Costa Wilson Luiz,Claro Laura Carolina Lopez,Coimbra Felipe José Fernandez,Dettino Aldo Lourenço Abbade,Riechelmann Rachel P.,Curado Maria Paula
Abstract
AbstractLittle is known about the features and outcomes of Brazilian patients with pancreatic cancer. We sought to describe the socio-economic characteristics, patterns of health care access, and survival of patients diagnosed with malignant pancreatic tumors from 2000 to 2014 in São Paulo, Brazil. We included patients with malignant exocrine and non-classified pancreatic tumors according to the International Classifications of Disease (ICD)-O-2 and -O-3, diagnosed from 2000 to 2014, who were registered in the FOSP database. Prognostic factors for overall survival (OS) in the subgroup of patients with ductal or non-specified (adeno)carcinoma were evaluated using Cox proportional hazard model. The study population consists of 6855 patients. Median time from the first visit to diagnosis and treatment were 13 (Interquartile range [IQR] 4–30) and 24 (IQR 8–55) days, respectively. Both intervals were longer for patients treated in the public setting. Median OS was 4.9 months (95% confidence interval [95% CI] 4.7–5.2). Increasing age, male gender, lower educational level, treatment in the public setting, absence of treatment, advanced stage, and treatment from 2000 to 2004 were associated with inferior OS. From 2000–2004 to 2010–2014, no improvement in OS was seen for patients treated in the public setting. Survival of patients with malignant pancreatic tumors remains dismal. Socioeconomical variables, especially health care funding, are major determinants of survival. Further work is necessary to decrease inequalities in access to medical care for patients with pancreatic cancer in Brazil.
Funder
Cancer Prevention and Research Institute of Texas
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Fitzmaurice, C. et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol. 388, 1459–1544 (2016).
2. da Fonseca, A. & Rego, M. Tendência da Mortalidade por Câncer de Pâncreas em Salvador—Brasil, 1980 a 2012. Rev. Bras. Cancerol. 62, 9–16 (2016).
3. Barbosa, I. R., dos Santos, C. A. & de Souza, D. L. B. Pancreatic cancer in Brazil: Mortality trends and projections until 2029. Arquivos de Gastroenterol. 55, 230–236 (2018).
4. de Souza, L. M. P., Moreira, J. P. L., Fogaça, H. S., Luiz, R. R. & de Souza, H. S. Pancreatic cancer incidence and lethality rates in Brazil. Pancreas 46, 699–706 (2017).
5. Tas, F. et al. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Int. J. Clin. Oncol. 18, 839–846 (2013).
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献